Skip to main content

Advanced Psychopharmacology: Mood and Substance Use Disorders

A comprehensive guide to the neurobiological foundations, pharmacotherapy, and clinical safety considerations for managing mood disorders and substance use disorders.

Save this reading to your study set

Sign up free

Mastering advanced psychopharmacology requires more than just memorizing drug names; it demands a deep understanding of how neurobiological mechanisms translate into clinical interventions. This guide focuses on the core pillars of mood disorders and substance use disorders, providing a structured review of neurotransmitter actions, medication classes, and critical safety considerations necessary for advanced clinical practice.

Neurobiological Foundations of Mood Disorders

Diagram illustrating the mechanism of action for Selective Serotonin Reuptake Inhibitors (SSRIs), showing how they block the reuptake of serotonin in the synapse, leading to increased serotonin levels.
Diagram illustrating the mechanism of action for Selective Serotonin Reuptake Inhibitors (SSRIs), showing how they block the reuptake of serotonin in the synapse, leading to increased serotonin levels.
The pharmacological management of mood disorders is heavily rooted in the monoamine hypothesis. This theory suggests that deficits in monoamine neurotransmitters—specifically serotonin (5HT), norepinephrine (NE), and dopamine (DA)—are central to the pathophysiology of depression.

Understanding the diversity of neurotransmitter actions is essential for tailoring treatment:

  • Serotonin (5HT): Primarily involved in mood, sleep, and anxiety regulation.
  • Norepinephrine (NE): Plays a key role in alertness, energy, and the stress response.
  • Dopamine (DA): Central to reward, motivation, and motor function.
  • GABA: The primary inhibitory neurotransmitter, crucial for regulating anxiety and impulsivity.

Exam Tip: When analyzing clinical scenarios, differentiate between impulsivity (acting without thought) and compulsivity (repetitive behaviors driven by anxiety). These are regulated by different neural circuits and neurotransmitter balances.

Pharmacotherapy for Major Depressive Disorder (MDD)

Treatment for MDD is categorized by the specific neurotransmitter systems the medications target.

First-Line and Common Antidepressants

  • Selective Serotonin Reuptake Inhibitors (SSRIs): These are the primary treatment for MDD. Clinicians must monitor for discontinuation syndrome, drug-induced activation, and the potential for exacerbating panic symptoms.
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): These target both serotonin and norepinephrine systems.
  • Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs): These target NE and DA, often used when different side effect profiles are needed.
  • Serotonin Antagonists and Reuptake Inhibitors (SARIs): These provide a different mechanism by blocking certain serotonin receptors while inhibiting reuptake.

Keep reading for free.

Create an account to finish this reading and make it part of your study routine.

Continue reading free

Already have an account? Log in

Updated

Study it your way.

Import this reading into your study set to get started with another study mode.

Make it your own.

Keep this reading in a new study set, or add it to one you already use.

Get started freeLog in